PMC:7696151 / 106650-106999
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
4032 | 206-209 | Gene | denotes | CD4 | Gene:920 |
4033 | 274-277 | Gene | denotes | CD8 | Gene:925 |
4034 | 283-286 | Gene | denotes | CD4 | Gene:920 |
4035 | 310-314 | Gene | denotes | IL-6 | Gene:3569 |
4049 | 108-116 | Species | denotes | patients | Tax:9606 |
4127 | 129-132 | Chemical | denotes | HCQ | MESH:D006886 |
4128 | 164-167 | Chemical | denotes | HCQ | MESH:D006886 |
4171 | 93-107 | Disease | denotes | HIV-1 infected | MESH:D015658 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T728 | 0-349 | Sentence | denotes | Paton, et al. (2015) [24] Randomized, double-blind, placebo-controlled trial83 asymptomatic HIV-1 infected patients 400 mg/day HCQ or placebo48 weeks At 48th in HCQ group is revealed a faster decline of CD4+ T-cell counts; no change in activation/proliferation levels in CD8+ and CD4+ T-cells; no change in IL-6 levels; an increase in viral load. |